Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Biosensors as diagnostic tools in clinical applications

Lino, C., Barrias, S., Chaves, R., Adega, F., Martins‐Lopes, P., & Fernandes, J. R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188726 · Cited by 175

Designed endocytosis-inducing proteins degrade targets and amplify signals

Huang, B., Abedi, M. H., Ahn, G., Coventry, B., Sappington, I., Tang, C., Wang, R., Schlichthaerle, T., Zhang, J. Z., Wang, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07948-2 · Cited by 174

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

Hirano, T., Yasuda, H., Tani, T., Hamamoto, J., Oashi, A., Ishioka, K., Arai, D., Nukaga, S., Miyawaki, M., Kawada, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5887 · Cited by 165

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Chen, P., Huang, H., Wáng, Y., Jin, J., Long, W., Chen, K., Zhao, X.-H., Chen, C.-G., & Li, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1234-8 · Cited by 165

EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells

Talukdar, S., Emdad, L., Das, S. K., & Fisher, P. B. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.003 · Cited by 165

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

Yuan, J., Mehta, P. P., Yin, M.-J., Sun, S., Zou, A., Chen, J. W., Rafidi, K., Feng, Z., Nickel, J., Engebretsen, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0185 · Cited by 168

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease

Hiley, C. T., Quesne, J. P. C. L., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31340-x · Cited by 167

Molecular histology of lung cancer: From targets to treatments

Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.008 · Cited by 163

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160

Comparison of Targeted Next‐Generation Sequencing (NGS) and Real‐Time PCR in the Detection of EGFR, KRAS, and BRAF Mutations on Formalin‐Fixed, Paraffin‐Embedded Tumor Material of Non‐Small Cell Lung Carcinoma—Superiority of NGS

Tuononen, K., Mäki‐Nevala, S., Sarhadi, V. K., Wirtanen, A., Rönty, M. J., Salmenkivi, K., Andrews, J. M., Telaranta-Keerie, A., Hannula, S., Lagström, S., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22047 · Cited by 164

Regulation of EGFR nanocluster formation by ionic protein-lipid interaction

Wang, Y., Gao, J., Guo, X., Tong, T., Shi, X., Li, L., Qi, M., Wang, Y., Cai, M., Jiang, J., et al. (2014) · Cell Research · doi:10.1038/cr.2014.89 · Cited by 160

Receptor Tyrosine Kinases and Targeted Cancer Therapeutics

Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159

Leveraging big data to transform target selection and drug discovery

Chen, B., & Butte, A. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.318 · Cited by 165

Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion

Deng, J., Shimamura, T., Perera, S. A., Carlson, N. E., Cai, D. D., Shapiro, G. I., Wong, K., & Letai, A. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1961 · Cited by 160

Detection of post-translational modifications in single peptides using electron tunnelling currents

Ohshiro, T., Tsutsui, M., Yokota, K., Furuhashi, M., Taniguchi, M., & Kawai, T. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.193 · Cited by 159

Protein kinase biochemistry and drug discovery

Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 166

Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling

Kanda, R., Kawahara, A., Watari, K., Murakami, Y., Sonoda, K., Maeda, M., Fujita, H., Kage, M., Uramoto, H., Costa, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4502 · Cited by 162

Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients

Lu, K. V., Zhu, S., Cvrljevic, A. N., Huang, T., Sarkaria, S. M., Ahkavan, D., Dang, J. H. T., Dinca, E. B., Plaisier, S. B., Oderberg, I. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0347 · Cited by 159

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy

Ricciuti, B., Mencaroni, C., Paglialunga, L., Paciullo, F., Crinò, L., Chiari, R., & Metro, G. (2016) · Medical Oncology · doi:10.1007/s12032-016-0731-2 · Cited by 157

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

Gazdar, A. F., Robinson, L. D., Oliver, D., Xing, C., Travis, W. D., Soh, J., Toyooka, S., Watumull, L. M., Xie, Y., Kernstine, K. H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000130 · Cited by 156

Molecular biomarkers for lung adenocarcinoma

Calvayrac, O., Pradines, A., Tostivint, E. P., Mazières, J., & Guibert, N. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 160

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155

β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells

Morello, V., Cabodi, S., Sigismund, S., Leal, M. D. P. C., Repetto, D., Volante, M., Papotti, M. G., Turco, E., & Defilippi, P. (2011) · Oncogene · doi:10.1038/onc.2011.107 · Cited by 155

Cancer invasion and resistance: interconnected processes of disease progression and therapy failure

Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 159

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Cho, B. C., Ahn, M., Kang, J. H., Soo, R. A., Reungwetwattana, T., Yang, J. C., Çiçin, İ., Kim, D., Wu, Y.-L. L. C., Lü, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00515 · Cited by 155

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

Weber, B., Meldgaard, P., Hager, H., Wu, L., Wei, W., Tsai, J., Khalil, A. A., Nexø, E., & Sørensen, B. S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-294 · Cited by 154

The HER family and cancer: emerging molecular mechanisms and therapeutic targets

Sergina, N. V., & Moasser, M. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.002 · Cited by 172

Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Shimamura, T., Li, D., Ji, H., Haringsma, H. J., Liniker, E., Borgman, C. L., Lowell, A. M., Minami, Y., McNamara, K. L., Perera, S. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5428 · Cited by 153

Emerging therapies for non-small cell lung cancer

Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Zeng, Q., Wang, J., Cheng, Z., Chen, K., Johnström, P., Varnäs, K., Li, D. Y., Yang, Z. F., & Zhang, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01073 · Cited by 151

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study

Boch, C., Kollmeier, J., Roth, A. J., Stephan-Falkenau, S., Misch, D., Grüning, W., Bauer, T. T., & Mairinger, T. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002560 · Cited by 151

Developments of CRBN-based PROTACs as potential therapeutic agents

Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 158

Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Gazdar, A. F., Gao, B., & Minna, J. D. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.12.005 · Cited by 157

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

Selinger, C. I., Rogers, T.-M., Russell, P. A., O'Toole, S. A., Yip, P. Y., Wright, G. M., Wainer, Z., Horvath, L. G., Boyer, M. J., McCaughan, B. C., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.87 · Cited by 150

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy

Teng, Y. H.-F., Tan, W.-J., Thike, A., Cheok, P. Y., Tse, G. M.-K., Wong, N.-S., Yip, G. W. C., Bay, B., & Tan, P. (2011) · Breast Cancer Research · doi:10.1186/bcr2857 · Cited by 150

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer

Rosa, V. D., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Vecchio, S. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0375 · Cited by 152

Receptor tyrosine kinase inhibitors in cancer

Ebrahimi, N., Fardi, E., Ghaderi, H., Palizdar, S., Khorram, R., Vafadar, R., Ghanaatian, M., Rezaei‐Tazangi, F., Baziyar, P., Ahmadi, A., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04729-4 · Cited by 150

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

Gahr, S., Stoehr, R., Geissinger, E., Ficker, J. H., Brueckl, W. M., Gschwendtner, A., Gattenloehner, S., Fuchs, F. S., Schulz, C. K. J., Rieker, R. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.511 · Cited by 150

MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling

Xu, K., Chen, G., Li, X., Wu, X., Chang, Z., Xu, J., Zhu, Y. T., Yin, P., Liang, X., & Dong, L. (2017) · Scientific Reports · doi:10.1038/srep41718 · Cited by 152

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 150

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Brewer, M. R., Yun, C., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 152

Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations

Seeliger, M. A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D. E., Shah, N. P., Kuriyan, J., & Maly, D. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3953 · Cited by 148

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

Parikh, K., Cang, S., Sekhri, A., & Liu, D. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0078-0 · Cited by 148

Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

Park, S. E., Tisch, A. H., Cho, E. Y., Shim, Y. M., Kim, J., Kim, H. S., Lee, J., Park, Y. H., Ahn, J. S., Park, K., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a94af4 · Cited by 145

Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation

Stahlhut, C. E., & Slack, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1003008 · Cited by 147

Combinational strategies of metformin and chemotherapy in cancers

Zhang, H., & Guo, X. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3037-3 · Cited by 145

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Ahn, M., Han, J., Lee, K. H., Kim, S.-W., Kim, D., Lee, Y., Cho, E. K., Kim, J.-H., Lee, G., Lee, J.-S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30504-2 · Cited by 145

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer

Bae, G.-Y., Choi, S., Lee, J., Jo, J., Lee, J., Kim, J., & Cha, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1463 · Cited by 147

Forkhead box M1 transcription factor: A novel target for cancer therapy

Wang, Z. P., Ahmad, A., Li, Y., Banerjee, S., Kong, D., & Sarkar, F. H. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.11.006 · Cited by 145

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation

Rho, J. K., Choi, Y. J., Kim, S. Y., Kim, T. W., Choi, E. K., Yoon, S.-J., Park, B. M., Park, E., Bae, J. H., Choi, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1103 · Cited by 144

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 143

Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc

Getlik, M., Grütter, C., Simard, J. R., Klüter, S., Rabiller, M., Rode, H. B., Robubi, A., & Rauh, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002928 · Cited by 142

Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )

Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 145

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

Bronte, G., Rizzo, S., Paglia, L. L., Adamo, V., Siragusa, S. M., Ficorella, C., Santini, D., Bazan, V., Colucci, G., Gebbia, N., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70016-5 · Cited by 141

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

Kancha, R. K., von Bubnoff, N. C. C., Bartosch, N., Peschel, C., Engh, R. A., & Duyster, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026760 · Cited by 140

ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion

Long, W., Foulds, C. E., Qin, J., Liu, J., Chen, D., Lonard, D. M., Solis, L. M., Wistuba, I. I., Qin, J., Tsai, S. Y., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61492 · Cited by 140

The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications

Zheng, H., Zhan, Y., Liu, S., Lu, J., Luo, J., Feng, J., & Fan, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0901-5 · Cited by 143

An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy

Wang, Y., Santos, A., Evdokiou, A., & Lošić, D. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00956a · Cited by 140

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138

Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities

Vallath, S., Hynds, R. E., Succony, L., Janes, S. M., & Giangreco, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00146413 · Cited by 143

N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells

WANG, M., Ren, D., Guo, W., Huang, S., Wang, Z., Li, Q., Du, H., Song, L., & Peng, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3270 · Cited by 143

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

Petrelli, F., Borgonovo, K., Cabiddu, M., & Barni, S. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.005 · Cited by 141

Breast cancer: The translation of big genomic data to cancer precision medicine

Low, S., Zembutsu, H., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13463 · Cited by 142

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib

Zou, Y., Ling, Y., Sironi, J., Schwartz, E. L., Perez-Soler, R., & Piperdi, B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c7210 · Cited by 137

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 131

Gefitinib Radiosensitizes Non–Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity

Tanaka, T., Munshi, A., Brooks, C., Liu, J. X., Hobbs, M. L., & Meyn, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1606 · Cited by 129

Genomic alterations of ERBB receptors in cancer: clinical implications

Mishra, R., Hanker, A. B., & Garrett, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.22825 · Cited by 132

Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status

Ou, S. I., Ziogas, A., & Zell, J. A. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b27b15 · Cited by 129

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

Rodríguez‐Antona, C., Pallares, J., Montero‐Conde, C., Inglada‐Pérez, L., Castelblanco, E., Landa, I., Leskelä, S., Leandro-Garcia, L. J., López-Jiménez, E. A., Letón, R., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0304 · Cited by 127

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

Tang, Z.-H., & Lu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.004 · Cited by 127

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131

ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer

Tasaki, M., Shimada, K., Kimurâ, H., Tsujikawa, K., & Konishi, N. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606012 · Cited by 126

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 129

Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

Yi, H. G., Kim, H. J., Kim, Y. J., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Kim, C. S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.016 · Cited by 125

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer

Attolini, C. S., Cheng, Y.-K., Beroukhim, R., Getz, G. A., Abdel-Wahab, O. I., Levine, R. L., Mellinghoff, I. K., & Michor, F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009117107 · Cited by 128

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC

Che, T.-F., Lin, C.-W., Wu, Y.-Y., Chen, Y., Han, C., Chang, Y., Wu, C., Hsiao, T.-H., Hong, T.-M., & Yang, P. (2015) · Oncotarget · doi:10.18632/oncotarget.5736 · Cited by 129

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131

Deregulation of cell signaling in cancer

Giancotti, F. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.005 · Cited by 133

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data

Jorge, S. E., Kobayashi, S. S., & Costa, D. B. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20144099 · Cited by 127

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients

Scharpenseel, H., Hanssen, A., Loges, S., Mohme, M., Bernreuther, C., Peine, S., Lamszus, K., Goy, Y., Petersen, C., Westphal, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43678-6 · Cited by 124

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 126

The GIST paradigm: lessons for other kinase‐driven cancers

Antonescu, C. R. (2010) · The Journal of Pathology · doi:10.1002/path.2798 · Cited by 123

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 124

Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor

Murakami, A., Takahashi, F., Nurwidya, F., Kobayashi, I., Minakata, K., Hashimoto, M., Nara, T., Kato, M., Tajima, K., Shimada, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086459 · Cited by 125

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group

Umemura, S., Tsubouchi, K., Yoshioka, H., Hotta, K., Takigawa, N., Fujiwara, K., Horita, N., Segawa, Y., Hamada, N., Takata, I., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.002 · Cited by 122

Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers

Sholl, L. M., Yeap, B. Y., Iafrate, A. J., Tisch, A. H., Chou, Y.-P., Wu, M., Goan, Y., Su, L., Benedettini, E., Yu, J. Q., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2477 · Cited by 122

EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor

Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121

KIT as a Therapeutic Target in Melanoma

Garrido, M. C., & Bastian, B. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.334 · Cited by 121

Cerebrospinal Fluid Concentrations of Gefitinib in Patients With Lung Adenocarcinoma

Zhao, J., Chen, M., Zhong, W., Zhang, L., Li, L., Xiao, Y., Nie, L., Hu, P., & Wang, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.004 · Cited by 121

An intravascular magnetic wire for the high-throughput retrieval of circulating tumour cells in vivo

Vermesh, O., Aalipour, A., Ge, T. J., Sáenz, Y., Guo, Y., Alam, I. S., Park, S.-M., Adelson, C. N., Mitsutake, Y., Vilches-Moure, J. G., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0257-3 · Cited by 122

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121

EGFR signaling and autophagy dependence for growth, survival, and therapy resistance

Jutten, B., & Rouschop, K. M. A. (2013) · Cell Cycle · doi:10.4161/cc.27518 · Cited by 121

Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses

Yang, X., Zhang, X., Mortenson, E. D., Radkevich-Brown, O., Wang, Y., & Fu, Y. (2012) · Molecular Therapy · doi:10.1038/mt.2012.184 · Cited by 120

Induced-fit docking studies of the active and inactive states of protein tyrosine kinases

Zhong, H. A., Tran, L. M., & Stang, J. L. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.08.012 · Cited by 120

Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition

Yen, H.-Y., Liu, Y.-C., Chen, N.-Y., Tsai, C.-F., Wang, Y.-T., Chen, Y.-J., Hsu, T.-L., Yang, P.-C., & Wong, C.-H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507329112 · Cited by 119

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 121

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156